Boryung's challenge against Eisai’s blockbuster anticancer drug Lenvima is gathering pace.

As the only domestic pharmaceutical company to continue the patent challenge, Boryung’s journey has passed the 70% mark. With only one patent remaining, expectations of the company’s launch of the Lenvima generic in 2025 are rising.

According to industry sources on the 1st, the Intellectual Property Trial and Appeal Board ruled in favor of Boryung that it had filed to invalidate Eisai’s anticancer drug Lenvima (lenvatinib)’s patent for "high purity quinoline derivatives and methods of manufacturing the same.”

#i1#The patent that had been in question was registered by Eisai in June